Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Exclusion Criteria

• •Patients who have undergone HSCT within 60 days
• •Patients who received systemic anticancer therapy or radiotherapy \<14 days prior to their first day of study drug administration
• •Patients who received an investigational agent \<14 days prior
• •Patients who are pregnant or breast feeding
• •Patients with an active severe infection who require anti-infective therapy or with an unexplained fever \>38.5°C during Screening visits or on their first day of study drug administration (at the discretion of the Investigator, patients with tumor fever may be enrolled)
• •Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF \<40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1
• •Patients with a history of myocardial infarction within the last 6 months
• •Patients with known unstable or uncontrolled angina pectoris
• •Patients with a known history of severe and/or uncontrolled ventricular arrhythmias
• •Patients with QTc interval ≥450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events
• •Patients taking medications that are known to prolong the QT interval
• •Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C
• •Patients with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during Screening
• •Patients with immediately life-threatening, severe complications of hematologic malignancies such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation